Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for serious medical conditions. Founded in 2000, the company has made significant strides in the fields of regenerative medicine and cell therapy, particularly in the treatment of cardiovascular diseases and Duchenne muscular dystrophy (DMD). Capricor's flagship product, CAP-1002, is a unique allogeneic cardiosphere-derived cell therapy that aims to improve heart function in patients with advanced heart failure. The company has garnered attention for its robust clinical trial results and commitment to advancing therapeutic options in underserved patient populations. With a strong market position and a dedication to scientific excellence, Capricor Therapeutics continues to lead the way in transforming the landscape of regenerative medicine.
DitchCarbon Score
How does Capricor Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Capricor Therapeutics, Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Capricor Therapeutics, Inc.'s reported carbon emissions
Capricor Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Capricor may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and climate commitments. However, without specific initiatives or targets, Capricor's position remains unclear in comparison to its peers. As the industry evolves, it may be beneficial for Capricor to consider developing measurable climate strategies to align with broader environmental goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Capricor Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
